Hanoi (VNA) – The Vietnamese Academy of Sciences and Technologies (VAST) announced the results of preclinical research on a herbal medicine for COVID-19[female[feminine treatment called VIPDERVIR at an online press conference on August 10.
Addressing the event, VAST Vice President Chu Hoang Ha said that since the start of the COVID-19 pandemic in early 2020, the academy has conducted studies in the service of prevention and control. of COVID-19.
Recently, on June 28, 2021, a research team from the VAST Institute of Chemistry found a method to shorten the synthesis of the anti-SARS-CoV-2 drug from Favipiravir.
Ha said that the VAST Biotechnology Institute, together with Vinh Gia Pharmaceutical JSC and Vietnam Chemical Pharmaceutical JSC, has researched and mastered a technology for manufacturing drugs for COVID-19 treatment from Vietnamese herbs called VIPDERVIR .
The National Biomedical Research Ethics Committee under the Ministry of Health agreed to approve the clinical study protocol of the Institute of Drug Biotechnology VIPDERVIR for COVID-19 patients at a meeting on August 7 .
The head of the traditional medicine management department of the Ministry of Health, Nguyen The Thinh, said that the VIPDERVIR is made up of several Vietnamese herbs containing active ingredients with valuable biopharmaceutical properties.
According to associate professor, Dr Le Quang Huan, who is leading the project, the main effects of this drug are to prevent the adhesion of the virus to cells, to block the ability of the virus to enter cells, to inhibit the ability of viruses to multiply. in cells and activate immune cells so that they can recognize, block and eliminate virus particles./.